Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory W Mattingly

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
CNS Spectrums|July 8, 2017
Beyond the pill: new medication delivery options for ADHDAndrew J Cutler, Gregory W Mattingly
CNS Spectrums|January 4, 2017
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systemsGregory W Mattingly, Richard H Anderson
Expert Review of Neurotherapeutics|March 19, 2024
Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescentsVladimir Maletic, Gregory W Mattingly, Jami Earnest
Postgraduate Medicine|August 2, 2017
A clinician's guide to ADHD treatment optionsGregory W Mattingly, Joshua Wilson, Anthony L Rostain
Translational Psychiatry|June 26, 2023
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorderAndrew J Cutler, Gregory W Mattingly, Vladimir Maletic
CNS Spectrums|October 30, 2020
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agentsAndrew J Cutler, Gregory W Mattingly, Rakesh Jain, et al.
Postgraduate Medicine|June 21, 2024
Are all ADHD medications created equal? Exploring the differences that enable evening dosingGregory W Mattingly, Julie A Carbray, Perry Roy, et al.
Current Medical Research and Opinion|March 8, 2023
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studiesGregory W Mattingly, Oscar Necking, Simon Nitschky Schmidt, et al.
CNS Spectrums|February 18, 2022
Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregiversSylvie Stacy, Gregory D Salinas, Emily Belcher, et al.
Journal of Clinical Psychopharmacology|July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity DisorderGregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
CNS Spectrums|July 8, 2017
Beyond the pill: new medication delivery options for ADHDAndrew J Cutler, Gregory W Mattingly
CNS Spectrums|January 4, 2017
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systemsGregory W Mattingly, Richard H Anderson
Expert Review of Neurotherapeutics|March 19, 2024
Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescentsVladimir Maletic, Gregory W Mattingly, Jami Earnest
Postgraduate Medicine|August 2, 2017
A clinician's guide to ADHD treatment optionsGregory W Mattingly, Joshua Wilson, Anthony L Rostain
Translational Psychiatry|June 26, 2023
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorderAndrew J Cutler, Gregory W Mattingly, Vladimir Maletic
CNS Spectrums|October 30, 2020
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agentsAndrew J Cutler, Gregory W Mattingly, Rakesh Jain, et al.
Postgraduate Medicine|June 21, 2024
Are all ADHD medications created equal? Exploring the differences that enable evening dosingGregory W Mattingly, Julie A Carbray, Perry Roy, et al.
Current Medical Research and Opinion|March 8, 2023
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studiesGregory W Mattingly, Oscar Necking, Simon Nitschky Schmidt, et al.
CNS Spectrums|February 18, 2022
Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregiversSylvie Stacy, Gregory D Salinas, Emily Belcher, et al.
Journal of Clinical Psychopharmacology|July 2, 2025
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity DisorderGregory W Mattingly, Osman Turkoglu, Denise Chang, et al.
Pageof 2